Analysts at Stifel Nicolaus assumed coverage on shares of Hinge Health (NYSE:HNGE - Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat.com reports. The brokerage set a "buy" rating and a $48.00 price target on the stock. Stifel Nicolaus' price target points to a potential upside of 20.63% from the company's previous close.
A number of other analysts have also issued reports on the stock. Canaccord Genuity Group started coverage on shares of Hinge Health in a research note on Monday. They set a "buy" rating and a $52.00 price target on the stock. Evercore ISI assumed coverage on Hinge Health in a research report on Monday. They set an "outperform" rating and a $50.00 price objective for the company. Needham & Company LLC assumed coverage on Hinge Health in a research report on Monday. They set a "buy" rating and a $47.00 price objective for the company. Bank of America assumed coverage on Hinge Health in a research report on Monday. They set a "buy" rating and a $42.00 price objective for the company. Finally, Royal Bank Of Canada assumed coverage on Hinge Health in a research report on Monday. They set an "outperform" rating and a $45.00 price objective for the company. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $46.00.
View Our Latest Analysis on HNGE
Hinge Health Trading Up 4.7%
Shares of NYSE HNGE traded up $1.79 during trading on Monday, hitting $39.79. 771,425 shares of the company were exchanged, compared to its average volume of 1,215,089. Hinge Health has a 12-month low of $33.42 and a 12-month high of $43.80.
Hinge Health Company Profile
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
See Also
Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
